万邦医药 (301520.SZ)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(万邦医药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年第三季度2024年第二季度2024年第一季度2023年第四季度2023年第三季度2023年第二季度2023年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市前上市前
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 106,089,616.0897,042,213.8490,172,342.02101,152,904.8075,661,205.4392,933,998.9872,058,423.64
 营业收入(元) 106,089,616.0897,042,213.8490,172,342.02101,152,904.8075,661,205.4392,933,998.9872,058,423.64
二、营业总成本(元) 89,629,668.4676,549,146.0565,349,751.6771,286,155.5254,900,456.5860,366,121.7444,258,960.47
 营业成本(元) 65,857,682.5753,066,009.2047,825,532.4957,406,962.4937,441,467.5745,667,321.0234,018,050.44
 研发费用(元) 15,896,694.6216,412,834.4310,738,916.3910,628,336.2111,201,833.537,766,110.194,924,815.49
 营业税金及附加(元) 400,385.95385,949.42369,055.88391,209.38366,067.59244,708.31158,796.43
 销售费用(元) 2,096,540.001,274,192.11939,770.05748,125.70674,981.221,791,331.991,321,632.25
 管理费用(元) 5,916,812.256,219,322.736,809,525.676,386,732.385,378,169.025,032,350.833,877,474.83
 财务费用(元) -538,446.93-809,161.84-1,333,048.81-4,275,210.64-162,062.35-135,700.60-41,808.97
  其中:利息费用(元) ------115.79
  其中:利息收入(元) 541,804.93821,404.021,338,763.354,280,223.44164,127.15137,328.3248,949.72
 资产减值损失(元) -333,026.48-926,170.60-448,901.30116,824.74-604,784.03-652,388.90-313,732.11
 信用减值损失(元) -1,490,109.97-816,605.92-103,996.54-1,507,745.31324,859.65-1,336,753.50-133,496.60
三、其他经营收益
 加:公允价值变动收益(元) 8,663,754.165,103,813.196,879,458.322,927,999.99---
 加:投资收益(元) 709,186.03649,981.91679,300.01425,783.66271,229.10923,012.47813,019.17
 其他收益(元) 361,201.97447,555.69299,034.551,601,672.273,483,985.13474,474.25339,125.83
四、营业利润(元) 24,370,953.3324,968,081.8232,127,485.3933,431,284.6325,094,288.6931,976,221.5628,504,379.46
 加:营业外收入(元) 127,106.402,219,508.86291,700.00289,012.46147,942.38284,347.0336,284.46
 减:营业外支出(元) 13.465,700.5043,418.6218,743.39109.00-100,000.00
五、利润总额(元) 24,498,046.2727,181,890.1832,375,766.7733,701,553.7025,242,122.0732,260,568.5928,440,663.92
 减:所得税费用(元) 1,733,522.631,836,018.352,688,682.512,921,168.921,751,216.023,427,188.323,453,485.71
六、净利润(元) 22,764,523.6425,345,871.8329,687,084.2630,780,384.7823,490,906.0528,833,380.2724,987,178.21
(一)按经营持续性分类
  持续经营净利润(元) 22,764,523.6425,345,871.8329,687,084.2630,780,384.7823,490,906.0528,833,380.2724,987,178.21
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 22,764,523.6425,345,871.8329,687,084.2630,780,384.7823,490,906.0528,833,380.2724,987,178.21
 扣除非经常性损益后的净利润(元) 14,572,117.4618,583,108.1822,744,459.4626,865,477.5019,419,187.9127,366,000.0024,044,500.00
七、每股收益
 一、基本每股收益(元) 0.340.380.450.450.470.580.50
 二、稀释每股收益(元) 0.340.380.450.45--0.50
九、综合收益总额(元) 22,764,523.6425,345,871.8329,687,084.2630,780,384.7823,490,906.0528,833,380.2724,987,178.21
 归属于母公司所有者的综合收益总额(元) 22,764,523.6425,345,871.8329,687,084.2630,780,384.7823,490,906.0528,833,380.2724,987,178.21
公告日期 2024-10-252024-08-232024-04-202024-04-202023-10-252023-09-052024-04-20
审计意见(境内) 标准无保留意见

前瞻产业研究院